<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Oryzon Genomics Sa — News on 6ix</title>
    <link>https://6ix.com/company/oryzon-genomics-sa</link>
    <description>Latest news and press releases for Oryzon Genomics Sa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 25 Mar 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/oryzon-genomics-sa" rel="self" type="application/rss+xml" />
    <item>
      <title>ORYZON Strengthens Vafidemstat Patent Portfolio With U.S. Notice of Allowance</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-strengthens-vafidemstat-patent-portfolio-with-us-notice-of-allowance</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-strengthens-vafidemstat-patent-portfolio-with-us-notice-of-allowance</guid>
      <pubDate>Wed, 25 Mar 2026 12:00:00 GMT</pubDate>
      <description>Covers the use of vafidemstat for treating non-aggressive symptoms of Borderline Personality Disorder (BPD) MADRID, and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application US 17/439,575, entitled “Methods of treating borderline perso</description>
    </item>
    <item>
      <title>ORYZON Announces U.S. Patent Grant Covering Iadademstat Combinations with Venetoclax</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-announces-us-patent-grant-covering-iadademstat-combinations-with-venetoclax-1</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-announces-us-patent-grant-covering-iadademstat-combinations-with-venetoclax-1</guid>
      <pubDate>Mon, 23 Mar 2026 12:00:00 GMT</pubDate>
      <description>Key combination for the treatment of first-line AMLRecent data from an ongoing study in first-line AML showed a 100% overall response rate (ORR) with iadademstat in combination with venetoclax and azacitidine MADRID and CAMBRIDGE, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. pate</description>
    </item>
    <item>
      <title>ORYZON Expands Patent Protection for Iadademstat with Grant Decision in Mexico Covering Combinations with PD-1/PD-L1 Inhibitors</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-expands-patent-protection-for-iadademstat-with-grant-decision-in-mexico-covering-combinations-with-pd-1pd-l1-inhibitors</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-expands-patent-protection-for-iadademstat-with-grant-decision-in-mexico-covering-combinations-with-pd-1pd-l1-inhibitors</guid>
      <pubDate>Thu, 12 Mar 2026 12:00:00 GMT</pubDate>
      <description>Key combination for the treatment of Small Cell Lung Cancer MADRID and CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the Mexican Patent Office has issued a decision to grant for its patent application MX/a/2021/011610, entitled “Combinations of iadademstat for cancer therapy”. The allowed claims protect the use of iadademstat in combinatio</description>
    </item>
    <item>
      <title>ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-reports-financial-results-and-corporate-update-for-quarter-ended-december-31st-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-reports-financial-results-and-corporate-update-for-quarter-ended-december-31st-2025</guid>
      <pubDate>Fri, 27 Feb 2026 17:29:00 GMT</pubDate>
      <description>Strong cash position at year-end 2025: $33.3 million (€28.4 million) CNS(Vafidemstat) Appointed renowned Rolando Gutierrez-Esteinou, M.D. as new CMO for CNSPreparing protocol resubmission to incorporate FDA guidance on Phase III PORTICO-2 trial in aggression in BPDOngoing expansion of Phase IIb schizophrenia trial into additional EU countriesFinalizing preparations for new Phase II trial in aggression in autism spectrum disorder as a part of the IPCEI EU Grant in personalized medicine Oncology –</description>
    </item>
    <item>
      <title>ORYZON Receives European Medicines Agency Approval to Initiate a Phase II Study of iadademstat in Essential Thrombocythemia</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-receives-european-medicines-agency-approval-to-initiate-a-phase-ii-study-of-iadademstat-in-essential-thrombocythemia</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-receives-european-medicines-agency-approval-to-initiate-a-phase-ii-study-of-iadademstat-in-essential-thrombocythemia</guid>
      <pubDate>Tue, 24 Feb 2026 13:00:00 GMT</pubDate>
      <description>MADRID and CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that the European Medicines Agency (EMA) has authorized its Clinical Trial Application (CTA) to initiate a Phase II study of iadademstat, Oryzon’s potent and selective LSD1 inhibitor currently in clinical development in oncology and hematology, for the treatment of essential thro</description>
    </item>
    <item>
      <title>ORYZON to Participate in Upcoming Events in February and March</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-to-participate-in-upcoming-events-in-february-and-march</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-to-participate-in-upcoming-events-in-february-and-march</guid>
      <pubDate>Thu, 19 Feb 2026 13:00:00 GMT</pubDate>
      <description>MADRID and CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: Bio-Neuroscience 2026, February 24-27Location: Hotel Jakarta, Amsterdam SmallCap Event 20th Edition, March 17Location: Les Salons Hoche, Paris BIO-Europe Spring 2026, March 23-25Location: Feira Internacional de Lisboa (</description>
    </item>
    <item>
      <title>ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-announces-appointment-of-rolando-gutierrez-esteinou-md-as-chief-medical-officer-for-cns</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-announces-appointment-of-rolando-gutierrez-esteinou-md-as-chief-medical-officer-for-cns</guid>
      <pubDate>Thu, 12 Feb 2026 13:00:00 GMT</pubDate>
      <description>Based in New Jersey (USA), to lead ORYZON’s CNS clinical development MADRID and CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer, CNS Programs. Dr. Gutierrez-Esteinou is a Harvard-trained psychiatrist and an accomplished global clinical development executive with more tha</description>
    </item>
    <item>
      <title>ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in Extensive Stage Small Cell Lung Cancer</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-announces-first-patient-dosed-in-an-investigator-initiated-phase-ib-study-of-iadademstat-in-extensive-stage-small-cell-lung-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-announces-first-patient-dosed-in-an-investigator-initiated-phase-ib-study-of-iadademstat-in-extensive-stage-small-cell-lung-cancer</guid>
      <pubDate>Mon, 09 Feb 2026 13:00:00 GMT</pubDate>
      <description>Exploring the combination with atezolizumab and radiation therapyStudy led by Yale University MADRID, Spain and CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, announced today that the first patient has been dosed in an investigator-initiated Phase Ib dose-finding trial evaluating iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with ra</description>
    </item>
    <item>
      <title>ORYZON Strengthens Patent Portfolio for Vafidemstat With New Decision to Grant in Japan</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-strengthens-patent-portfolio-for-vafidemstat-with-new-decision-to-grant-in-japan</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-strengthens-patent-portfolio-for-vafidemstat-with-new-decision-to-grant-in-japan</guid>
      <pubDate>Mon, 02 Feb 2026 13:00:00 GMT</pubDate>
      <description>For the treatment of aggression and social withdrawal MADRID and CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that it has received a “Decision to grant” communication from the Japanese Patent Office for its patent application JP2023-136283, titled “Methods of treating behavior alterations”, related to vafidemstat, Oryzon’s LSD1 inhibitor in c</description>
    </item>
    <item>
      <title>ORYZON to Participate in Upcoming Events in January</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-to-participate-in-upcoming-events-in-january</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-to-participate-in-upcoming-events-in-january</guid>
      <pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
      <description>MADRID and CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: 9th Sachs Annual Neuroscience Innovation Forum, January 11Location: Marines’ Memorial Club, San Francisco, USAPresentation type: Company presentationPresentation time: 10:35 am (PST) 44th Annual J.P. Morgan Healthcare C</description>
    </item>
    <item>
      <title>ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-expands-global-patent-protection-for-iadademstat-with-grant-decision-in-japan-covering-combinations-with-pd-1pd-l1-inhibitors</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-expands-global-patent-protection-for-iadademstat-with-grant-decision-in-japan-covering-combinations-with-pd-1pd-l1-inhibitors</guid>
      <pubDate>Mon, 22 Dec 2025 13:00:00 GMT</pubDate>
      <description>Key combination for the treatment of Small Cell Lung CancerMADRID and CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the Japanese Patent Office has issued a Decision to Grant for its patent application JP2021-557187, entitled “Combinations of iadademstat for cancer therapy”. Following formal grant, the patent is expected to remain in force u</description>
    </item>
    <item>
      <title>ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders&apos; Meeting</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-announces-the-voting-results-of-december-2025-extraordinary-general-shareholders-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-announces-the-voting-results-of-december-2025-extraordinary-general-shareholders-meeting</guid>
      <pubDate>Mon, 15 Dec 2025 13:39:00 GMT</pubDate>
      <description>37.8% of voting rights present or representedAll resolutions were approved MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the results of voting at the Extraordinary General Shareholders&apos; Meeting held last Friday in Madrid. A total of 33,581,589 of the Company&apos;s issued and outstanding voting rights (representing 37.7938% of the share cap</description>
    </item>
    <item>
      <title>ORYZON Presents Data for Iadademstat Combinations in AML at the American Society of Hematology (ASH) 67th Annual Meeting</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-presents-data-for-iadademstat-combinations-in-aml-at-the-american-society-of-hematology-ash-67th-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-presents-data-for-iadademstat-combinations-in-aml-at-the-american-society-of-hematology-ash-67th-annual-meeting</guid>
      <pubDate>Tue, 09 Dec 2025 13:00:00 GMT</pubDate>
      <description>100% Overall response rate (ORR) in triple combo study with azacitidine and venetoclax in newly diagnosed AML patients80% CR and 90% Composite Complete Remissions (CCR); median OS not reached after 9 months and good tolerability70% of patients derived to Hematopoietic Stem Cell Transplantation (HSCT) 67% CCR at the expansion dose in study evaluating iadademstat plus gilterinib in FLT3-mutated relapsed/refractory AML patients; 47% CR+CRhTreatment was safe and well tolerated MADRID, SPAIN and CAMB</description>
    </item>
    <item>
      <title>ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-reports-financial-results-and-corporate-update-for-quarter-ended-september-30-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-reports-financial-results-and-corporate-update-for-quarter-ended-september-30-2025</guid>
      <pubDate>Fri, 07 Nov 2025 13:00:00 GMT</pubDate>
      <description>The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&amp;Green CNS(Vafidemstat) Received feedback from the FDA on Phase III PORTICO-2 trial in BPD; Company to revise protocol and resubmitReinforcing company’s clinical, strategy and regulatory teamsExpansion of ongoing Phase IIb in schizophrenia into other EU countries continuesPreparations continue for new Phase II trial in aggression in Autism</description>
    </item>
    <item>
      <title>ORYZON Announces Positive Clinical Data of Iadademstat at ASH-2025</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-announces-positive-clinical-data-of-iadademstat-at-ash-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-announces-positive-clinical-data-of-iadademstat-at-ash-2025</guid>
      <pubDate>Tue, 04 Nov 2025 13:00:00 GMT</pubDate>
      <description>Three iadademstat abstracts have been accepted for presentation at the upcoming ASH-2025 Annual MeetingPreliminary data from the ongoing Phase Ib trial combining iadademstat with azacitidine and venetoclax in newly diagnosed, unfit AML patients showed a 100% overall response rateUpdated preliminary data from the ongoing Phase Ib FRIDA trial evaluating iadademstat in combination with gilteritinib in FLT3-mutated relapsed/refractory AML showed a 67% response rate in the expanded dose, superior to</description>
    </item>
    <item>
      <title>ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-announces-firstpatientin-fpi-in-restore-phase-ib-trial-of-iadademstat-in-sickle-cell-disease</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-announces-firstpatientin-fpi-in-restore-phase-ib-trial-of-iadademstat-in-sickle-cell-disease</guid>
      <pubDate>Mon, 03 Nov 2025 13:00:00 GMT</pubDate>
      <description>Recently approved by the European Medicines Agency, RESTORE will evaluate iadademstat’s ability to raise fetal hemoglobin (HbF) in adult patients with SCDIadademstat has demonstrated a favorable safety and tolerability profile across ~200 patients in prior oncology clinical trials MADRID and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical‑stage biopharmaceutical company and global leader in epigenetics, today announced</description>
    </item>
    <item>
      <title>ORYZON to Participate in Upcoming Events in November</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-to-participate-in-upcoming-events-in-november</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-to-participate-in-upcoming-events-in-november</guid>
      <pubDate>Thu, 30 Oct 2025 12:00:00 GMT</pubDate>
      <description>MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: BIO-EUROPE, November 3-5Location: Viena Congress and Convention Center, Vienna, Austria LSX Investival Showcase Europe 2025, November 17Location: Old Billingsgate, London, United Kingdom Jefferies Global Healthca</description>
    </item>
    <item>
      <title>ORYZON Strengthens Regulatory Strategy with the Appointment of Dr. Iman Barilero as Senior Advisor for Regulatory Affairs</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-strengthens-regulatory-strategy-with-the-appointment-of-dr-iman-barilero-as-senior-advisor-for-regulatory-affairs</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-strengthens-regulatory-strategy-with-the-appointment-of-dr-iman-barilero-as-senior-advisor-for-regulatory-affairs</guid>
      <pubDate>Tue, 28 Oct 2025 12:00:00 GMT</pubDate>
      <description>To enhance and accelerate regulatory dialogue with the FDA To provide strategic guidance across clinical development programsTo bring deep expertise in CNS and immuno-oncology MADRID and CAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, BME: ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, is pleased to announce the strategic collaboration with Dr. Iman Barilero, PharmD, PhD, as Senior Advisor for Regulatory Affa</description>
    </item>
    <item>
      <title>ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-receives-feedback-from-the-fda-in-response-to-the-submitted-phase-iii-protocol-in-borderline-personality-disorder</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-receives-feedback-from-the-fda-in-response-to-the-submitted-phase-iii-protocol-in-borderline-personality-disorder</guid>
      <pubDate>Fri, 17 Oct 2025 16:08:00 GMT</pubDate>
      <description>Provides clarity on the aspects to incorporateCompany to address them and resubmit revised protocol MADRID, Spain and CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, BME: ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that it has received written feedback from the U.S. Food and Drug Administration (FDA) regarding the Phase III protocol to evaluate vafidemstat in borderline personality disorder</description>
    </item>
    <item>
      <title>ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors</title>
      <link>https://6ix.com/company/oryzon-genomics-sa/news/oryzon-strengthens-patent-portfolio-for-iadademstat-with-european-grant-decision-covering-combinations-with-pd1pd-l1-inhibitors</link>
      <guid isPermaLink="true">https://6ix.com/company/oryzon-genomics-sa/news/oryzon-strengthens-patent-portfolio-for-iadademstat-with-european-grant-decision-covering-combinations-with-pd1pd-l1-inhibitors</guid>
      <pubDate>Wed, 01 Oct 2025 12:00:00 GMT</pubDate>
      <description>MADRID and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and European leader in epigenetics, today announced that the European Patent Office (EPO) has issued a Decision to Grant for its patent application EP20712594.9, entitled “Combinations of iadademstat for cancer therapy”. The allowed claims protect the use of iadademstat in combination with PD1 or PD-L1 inhibitors for the treatment of canc</description>
    </item>
  </channel>
</rss>